---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-038758"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:38:20.276195+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Longeveron Q1 loss $4.6M, cash $13.7M; CFO resigns; HLHS survival 100% at 5 yrs

## Summary
- Net loss widened to $4.6M ($0.22/share) in Q1 2023 from $3.5M ($0.17/share) in Q1 2022.
- Cash and marketable securities fell to $13.7M at March 31, 2023 from $19.6M at Dec 31, 2022.
- CFO James Clavijo resigning effective June 9, 2023; external search for replacement ongoing.
- ELPIS I HLHS trial shows 100% survival up to 5 years vs historical 20% mortality for Lomecel-B.
- Topline results from CLEAR MIND Phase 2a Alzheimer's trial expected by end of 2023.

## SEC filing metadata
- accession: 0001213900-23-038758
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/0001213900-23-038758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/ea178436-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-038758
- JSON: https://secwatch.observer/filing/0001213900-23-038758.json
- Plain text: https://secwatch.observer/filing/0001213900-23-038758.txt

## Key facts
- Earnings Releases
  Longeveron Inc. reported the first quarter ended March 31, 2023 results: revenue $0.3 million, net income $4.6 million, EPS $0.22.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $0.3 million
  - Net income: $4.6 million
  - EPS: $0.22
  - Result: reported results
  source text: Revenue for the first quarters of 2023 and 2022 was $0.3 million and $0.4 million, respectively. Revenue consisted of: ● Clinical trial revenue, which comes from our Bahamas Registry Trial, for the three months ended March 31, 2023, and 2022 was $0.2 million and $0.3 million, respectively, representing a 23% decline, despite demand increasing in the first quarter of 2023 versus first quarter 2022. The Company experienced some discounts and one-time price adjustments that reduced overall revenue in the first quarter of 2023 for the Bahamas Registry Trial. ● Grant revenue for each of the three months ended March 31, 2023, and 2022 was $0.1 million. R&D Expenses: Research and development expenses in the first quarter 2023 were $2.8 million compared to $1.4 million for the same period in 2022. The increase of $1.4 million, or 94%, was primarily due to an increase of $1.1 million in research and development expenses that were not reimbursable by grants. Equity-based compensation allocated t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/0001213900-23-038758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.